| Literature DB >> 25972414 |
Amanda C Brown1, Josephine M Bryant2, Katja Einer-Jensen3, Jolyon Holdstock1, Darren T Houniet1, Jacqueline Z M Chan1, Daniel P Depledge4, Vladyslav Nikolayevskyy5, Agnieszka Broda5, Madeline J Stone6, Mette T Christiansen4, Rachel Williams4, Michael B McAndrew1, Helena Tutill4, Julianne Brown4, Mark Melzer7, Caryn Rosmarin7, Timothy D McHugh8, Robert J Shorten9, Francis Drobniewski5, Graham Speight1, Judith Breuer4.
Abstract
The rapid identification of antimicrobial resistance is essential for effective treatment of highly resistant Mycobacterium tuberculosis. Whole-genome sequencing provides comprehensive data on resistance mutations and strain typing for monitoring transmission, but unlike for conventional molecular tests, this has previously been achievable only from cultures of M. tuberculosis. Here we describe a method utilizing biotinylated RNA baits designed specifically for M. tuberculosis DNA to capture full M. tuberculosis genomes directly from infected sputum samples, allowing whole-genome sequencing without the requirement of culture. This was carried out on 24 smear-positive sputum samples, collected from the United Kingdom and Lithuania where a matched culture sample was available, and 2 samples that had failed to grow in culture. M. tuberculosis sequencing data were obtained directly from all 24 smear-positive culture-positive sputa, of which 20 were of high quality (>20× depth and >90% of the genome covered). Results were compared with those of conventional molecular and culture-based methods, and high levels of concordance between phenotypical resistance and predicted resistance based on genotype were observed. High-quality sequence data were obtained from one smear-positive culture-negative case. This study demonstrated for the first time the successful and accurate sequencing of M. tuberculosis genomes directly from uncultured sputa. Identification of known resistance mutations within a week of sample receipt offers the prospect for personalized rather than empirical treatment of drug-resistant tuberculosis, including the use of antimicrobial-sparing regimens, leading to improved outcomes.Entities:
Mesh:
Year: 2015 PMID: 25972414 PMCID: PMC4473240 DOI: 10.1128/JCM.00486-15
Source DB: PubMed Journal: J Clin Microbiol ISSN: 0095-1137 Impact factor: 5.948